WebbTorqur is a Swiss clinical-stage biotech company launched in 2024 as a subsidiary of Swiss Rockets, a Basel-based incubator and accelerator of start-up companies in oncology and … Webb1 sep. 2024 · Developer of targeted oncology and dermatology medicines intended for the treatment of cancer and genetic diseases. The company's medicines aim at extending …
Bimiralisib - PIQUR Therapeutics - AdisInsight - Springer
WebbA total of 184 patients were assessed with ages ranging from 20.2 to 83.1 years and the number of prior lines of therapy ranging from 0 to 16. At this latest data cutoff (January 15, 2024), median duration of OS follow-up was 29.2 months (95% CI, 28.6-30.0 months). WebbInvestors of Piqur Therapeutics include Versant Ventures and Swiss Commission of Technology and Innovation. Discover the right solution for your team The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. taxi service eagan mn
PQR309 in Patients With Relapsed or Refractory Primary Central …
Webb1 dec. 2024 · 5 PIQUR Therapeutics AG, Basel, Switzerland. 6 Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058, Basel, Switzerland. 7 Department of … Webb1 jan. 2024 · Here, we extensively characterized the in vitro and in vivo activity and the mechanism of action of PQR309 (bimiralisib), a novel oral selective dual PI3K/mTOR … Webb21 nov. 2024 · 2 PIQUR Therapeutics AG , Hochbergerstrasse 60 , 4057 Basel , Switzerland. 3 Department of Pharmacology, Toxicology, and Pharmacy , University of Veterinary Medicine Hannover, and Center for Systems Neuroscience , 30559 Hannover , Germany. the citation jet